saRNA Vaccine Partnerships
Precision NanoSystems has expertise using mRNA vector designs to development saRNA constructs.
Contact Us to Learn More
RNA Platform
As part of Precision Nanosystems' Genetic Medicine Toolkit, we provide partners access to RNA technology to advance genetic medicines that are revolutionizing treatment of cancer, rare disease and infectious disease.
How Genetic Medicine Works
Genetic medicines deliver nucleic acids that instruct cells to express, silence or modify a gene. Genetic medicines exploit pre-existing cellular processes to correct or reverse genetic abnormalities to treat diseases that were previously thought to be "undruggable" such as some rare diseases, cancers and infectious diseases.
Examples of Genetic Payloads
Edit Genes
The Advantage of mRNA
RNA medicine does not require nuclear delivery and transcription, making mRNA a simple solution for gene therapy.
The effects of mRNA are transient which is inherently safer than episomal systems, or those that integrate into the genome.
mRNA does not alter the gene itself but instead regulates expression.
An mRNA COVID-19 vaccines from Pfizer/BioNTech has recently received Emergency Use Authorization from the FDA.
Precision Nanosystems has assembled a team around the self-amplifying mRNA (saRNA) technology platform.
Types of mRNA
Unmodified mRNA
Elicits an immune response, ideal for immunotherapy applications
Base-modified mRNA
Modified mRNA that avoids immune response allowing for broader therapeutic applications
Self-amplifying mRNA
Encodes not only a protein but also the non-structural proteins that allow mRNA replication
What is Self-Amplifying mRNA?
Self-amplifying mRNA (saRNA) are a subclass of mRNA that that can replicate to produce more copies of mRNA by co-opting the cellular machinery.
Learn more by watching saRNA pioneer Dr. Andrew Geall's 2020 webinar.
The Advantages of a Lower Dose
Self-amplifying mRNA contain elements of the alphavirus genome which can mediate RNA replication in the cytosol. This replication allows for amplified antigen production while using a low mRNA dose.
Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Resource Center
Poster
September 01, 2022
Application Note
March 15, 2022
Publication - Abstract
July 01, 2020
Journal of Controlled Release
Publication - Abstract
May 08, 2020
Vaccines
Publication - Abstract
April 02, 2020
Journal of Controlled Release